Mirati Therapeutics Surges 45% on Speculation of Sanofi Acquisition Amid FDA Scrutiny of Amgen's KRAS G12C Inhibitor

On the same day, Amgen's KRAS G12C inhibitor was questioned by the FDA expert committee regarding the reliability of its Phase III validation clinical results. Affected by these two pieces of news, Mirati Therapeutics' stock price surged 45% on the day, with a current market value of $3.66 billion. Mirati Therapeutics’ leading pipeline product is the KRAS G12C inhibitor Adagrasib, which has already been approved for marketing.